Medicine and Dentistry
Kidney Metastasis
100%
Targeted Therapy
71%
Overall Survival
61%
Clear Cell Renal Cell Carcinoma
55%
Kidney Cancer
34%
Vasculotropin
32%
Clinical Trial
32%
Disease
27%
Progression Free Survival
20%
Nephrectomy
18%
Testis Cancer
18%
Oncologist
17%
Malignant Neoplasm
16%
Oncology
16%
Surgery
14%
Neoplasm
14%
Pazopanib
13%
Germinoma
13%
Cancer Cell
13%
Hazard Ratio
13%
Clear Cell
12%
Immune Checkpoint Inhibitor
11%
Immunoglobulin
11%
Cancer Research
11%
Clinician
10%
Treatment Duration
10%
High Risk Population
10%
Medical Oncology
9%
Combination Therapy
9%
COVID-19
9%
Germ Cell Cancer
9%
Adjuvant Therapy
9%
Papillary Renal Cell Carcinomas
9%
Paraneoplastic Syndrome
9%
Vasculotropin Inhibitor
9%
Urology
8%
Kidney Tumour
8%
Cancer
7%
Retroperitoneal Lymph Node Dissection
7%
Continuing Medical Education
7%
Metastatic Carcinoma
7%
Prognostic Factor
7%
Immunotherapy
6%
Prostate Cancer
6%
Sunitinib
6%
Sarcomatoid
6%
Brain Metastasis
5%
Urologist
5%
Lymph Node Metastasis
5%
High Dose Chemotherapy
5%
Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
58%
Targeted Therapy
38%
Overall Survival
27%
International Metastatic Renal Cell Carcinoma Database Consortium
19%
Kidney Cancer
18%
Clinical Trials
15%
Progression-free Survival
14%
Clinical Outcomes
13%
Renal Cell Carcinoma
13%
Germ Cell Tumor
12%
Medical Oncologist
12%
Canada
10%
Vascular Endothelial Growth Factor
9%
Combination Therapy
9%
Immune Checkpoint Inhibitor Therapy
9%
Locally Advanced Renal Cell Carcinoma
9%
Testis Cancer
9%
Prognostic Groups
9%
Paraneoplastic Syndrome
9%
Chemotherapy
9%
First-line Therapy
7%
Metastatic RCC
7%
Nivolumab
7%
Ipilimumab
7%
Immune Checkpoint Inhibitors
6%
Tumor
6%
Nephrectomy
6%
Genitourinary Malignancies
6%
Quality Indicators
6%
Renal Tumor
6%
Confidence Interval
6%
Favorable Intermediate Risk
5%
Progressive Disease
5%
Priority Setting Partnership
5%
Oncological Outcomes
5%
Practice Patterns
5%
Survival Outcomes
5%
Disease Control Rate
5%
Surgical Management
5%
Resection
5%
Post-chemotherapy
5%
Population-based
5%
Urologists
5%
Academic Center
5%
Immuno-oncology Agents
5%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
94%
Overall Survival
62%
Renal Cell Carcinoma
55%
Vasculotropin
28%
Progression Free Survival
25%
Sunitinib
23%
Disease
17%
Pazopanib
17%
Clinical Trial
16%
Kidney Cancer
14%
Placebo
13%
Vasculotropin Inhibitor
9%
Disease Free Survival
9%
Malignant Neoplasm
9%
Immune Checkpoint Inhibitor
9%
Protein Tyrosine Kinase Inhibitor
9%
Phase II Trials
9%
Nivolumab
6%
Ipilimumab
6%
Protein Tyrosine Kinase
6%
Vasculotropin Receptor
6%
Sorafenib
5%
Everolimus
5%
Lymph Node Metastasis
5%
Axitinib
5%